James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."
EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for
cancer. MKC-1 is an oral cell-cycle regulator with activity against the
mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a
selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The
Company also has an approved IND application for Panzem(R) in rheumatoid
arthritis. EntreMed's goal is to develop and commercialize new compounds
based on the Company's expertise in angiogenesis, cell-cycle regulation and
inflammation -- processes vital to the treatment of cancer and other
diseases, such as rheumatoid arthritis. Additional information about
EntreMed is available on the Company's web site at '/>"/>
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved